NRBO - Oramed to form joint venture with China-based Hefei Tianhui Biotech
2023-08-02 08:30:48 ET
More on Oramed
- Oramed: Buyer Beware
- Oramed's Chinese partner HTIT completes phase 3 oral insulin trial; submits marketing Application in China; stock Up 17%
- Oramed stock falls 10% as Wainwright cuts rating on potential halt of drug trial
- Oramed stock slumps ~70% as diabetes drug fails phase 3 study
- Oramed oral COVID vaccine shows promise in phase 1 trial
For further details see:
Oramed to form joint venture with China-based Hefei Tianhui Biotech